E.E. Geduld’s Esperion Therapeutics ESPR Stock Holding History

E.E. Geduld’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-7,500	Closed	-$613K	–	230
2015 Q2	$613K	Buy	7,500 +2,500	+50%	+$245K	0.38%	47
2015 Q1	$463K	Sell	5,000 -25,000	-83%	-$1.61M	0.31%	77
2014 Q4	$1.21M	Buy	+30,000	New	+$918K	0.65%	19

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

E.E. Geduld's ESPR Position: Q3 2015 in Review

E.E. Geduld sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 7,500 shares — an estimated $613K sold.

E.E. Geduld first reported a position in ESPR in Q4 2014 and held it in 3 quarters. The position peaked at $1.21M in Q4 2014. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

E.E. Geduld reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
E.E. Geduld sold 7,500 Esperion Therapeutics shares in Q3 2015, an estimated $613K.
E.E. Geduld first reported a position in Esperion Therapeutics in Q4 2014 and held it in 3 quarters.
E.E. Geduld's Esperion Therapeutics position peaked at $1.21M in Q4 2014.
121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.